Second Genome

Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases.

Second Genome headquartered in United States, North America, operates in the Biotechnology, Medical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $3.0B in funding across 48 round(s). With a team of 11-50 employees, Second Genome is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Second Genome, raised $6.5M. Discover more about their projects, partnerships, and impact on our platform.